Market Overview
The Lactated Ringers Injection Market is expected to reach a significant CAGR during the forecast period (2024-2031).
Lactated Ringer's injection replaces electrolyte and water loss in patients with low blood pressure or low blood volume. Lactated Ringer's injection is also used as an alkalinizing agent, which increases the pH level of the body.
Market Scope
| Metrics | Details |
| Market CAGR | High |
| Segments Covered | By Type, By Application, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To know more Insights Download Sample
Market Dynamics
After trauma, short-term fluid replacement and dehydration, and replacement of fluids and electrolytes will drive the Lactated Ringers Injection Market
After trauma, short-term fluid replacement and dehydration will drive the lactated ringers injection market
Ringer Lactate R Injection is used for short-term fluid replacement and dehydration. It comprises four medicines: sodium chloride, sodium lactate, potassium chloride, and calcium chloride that help replenish fluid loss. Thus, it treats hypovolemia that can result due to dehydration, injury, or burns. Ringer Lactate Injection must be administered under the supervision of a healthcare professional. Patients should not take it if they have any known allergy to this injection. The doctor may check blood pressure and suggest getting regular blood tests done while using this injection.
Fluid resuscitation in trauma patients aims to prevent a cardiac arrest due to severe hypovolaemia and achieve a satisfying level of mean arterial pressure to ensure adequate tissue perfusion. In trauma patients fluid resuscitation is indicated for traumatic hemorrhage, sympatholysis due to sedation or spinal injury, and vasoplegia due to inflammation (tissue attrition and ischaemiareperfusion). Recently, lactate solutions have been proposed as an alternative to mannitol in traumatic brain injury patients.
The replacement of fluids and electrolytes will drive the lactated ringers injection market
In lactated ringer's injection 5% dextrose provides electrolytes, calories and is a water source for hydration. Depending on the clinical condition of patient it is capable of inducing diuresis. This solution contains lactate which produces a metabolic alkalinizing effect. It restores fluid and electrolyte balances, produces diuresis, and acts as an alkalizing agent (reduces acidity).
In patients with low blood pressure or low blood volume lactated ringer's injection is used to replace water and electrolyte loss. As an alkalinizing agent, it is used to increase the pH level of the body. It is more beneficial than a saline solution as it doesn't remain in the body for as long and is less likely to cause fluid overload.
The addition of lactate reduces acidity as the body converts it into bicarbonate, a base element that helps regulate its pH balance. Acidosis commonly occurs when the liquid portion of the blood is too low, a condition called hypovolemia.
Side effects related to its use and route of administration will hamper the lactated ringers injection market
There is a fear of ringer’s lactate worsening lactic acidosis and causing hyperkalemia. Ringer’s lactate includes a concentration of potassium four mEq/L. Logically, if giving an additional hyperkalemic potassium a hyperkalemic would worsen hyperkalemia, this is not correct. Hyperkalemia in patients may worsen with metabolic acidosis. Large-volume IV administration of normal saline may consequently give patients a hyperchloremic non-anion gap metabolic acidosis. Ringer’s lactate does not have this effect. It also has a calcium concentration which prohibits the use of it as a diluent for blood transfusions. As an anticoagulant some blood products use citrate and when mixed with calcium it leads to the precipitation of calcium citrate. It may cause clotting and obstruction of the IV line.
In IV fluid administration, there is a possibility of edema and swelling. At-risk patients are those with chronic kidney disease, congestive heart failure, liver cirrhosis, and hypoalbuminemia. During IV administration, these patients must be monitored with serial physical exams to determine if they are becoming clinically hypervolemic.
COVID-19 Impact Analysis
COVID-19 has affected the healthcare industry. To curb its growth, government-imposed lockdown. People are fearful they will experience occupational effects and adverse health from the COVID-19 pandemic. This affects the lactated ringers injection market as many pharmaceutical industries have stopped manufacturing units.
Lactated Ringers Injection Market Segment Analysis
1000 ml segment will dominate the lactated ringers injection market
Lactated Ringer's Injection, USP, 1000 mL VIAFLEX Plastic Container. Lactated Ringers Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment in single-dose containers for intravenous administration. It contains no antimicrobial agents. Each Lactated Ringer's injection USP of 100 mL contains sodium chloride 600 mg, sodium lactate, anhydrous 310 mg, potassium chloride 30 g and calcium chloride, dihydrate 20 mg.
Penn Care manufactures IV Fluids, Lactated Ringers Injection USP, 1000 mL.
The human medical use segment will dominate the lactated ringers injection market
Lactated Ringer’s solution can be received by both adults and children. It is often the IV solution of choice if one has sepsis or infection so severe that body’s acid-base balance is thrown off. Doctors also use lactated Ringer’s as an irrigating solution. The solution is sterile. It can therefore be used to wash out a wound. It can also be used during surgery to irrigate the bladder or a surgical site. This helps to wash away bacteria or make a surgical site easier to see. Manufacturers don’t intend for people to drink lactated Ringer’s solution. It’s only meant for irrigation or IV use. Lactated Ringer's Injection USP is nonpyrogenic, sterile and contains no antimicrobial agents or bacteriostatic. This product is intended for intravenous administration in a single-dose container.
Lactated Ringer's Injection USP is a source of water for hydration and provides electrolytes. Depending on the the patients clinical condition it induces diuresis. This solution produces a metabolic alkalinizing effect because it contains lactate. The major cation of the extracellular fluid sodium, functions primarily to control fluid balance, water distribution and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid. Potassium, the principal cation of intracellular fluid, participates in carbohydrate utilization and protein synthesis and is critical in regulating nerve conduction and muscle contraction, particularly in the heart.
Market Geographical Share
North America region will dominate the lactated ringers injection market
This region will dominate the lactated ringers injection market with increased research and development activity and major key player's presence.
The US FDA has announced that ICU Medical voluntarily recalls a single lot of Lactated Ringer’s Injection, with the lot number 07-514-FW, nationwide in the US. According to the agency, the products are being recalled at the hospital and user level due to particulate matter identified as iron oxide. Through a single customer complaint ICU Medical became aware of this issue.
An American-managed company AdvaCare is a GMP manufacturer of Ringer Lactate infusion. Ringer lactate infusion is a non-pyrogenic, sterile solution used for electrolyte replacement. It has no antimicrobial agents and is hence not used to treat any microbial infections. Ringer lactate is also used in the treatment of burns, gastrointestinal fluid loss and acute blood loss.
Competitive Landscape
Major key players in the ICU Medical, B. Braun Medical Inc, Baxter, Vedco Inc, Dechra, Huazhong Pharmaceutical, Shanghai Hegno Pharmaceutical Holding Co., Ltd., and Nanjing Pharmaceutical Factory Co. Ltd.
B. Braun Medical Inc
Overview: A leader in infusion therapy and pain management, B. Braun Medical Inc. develops, manufactures, and markets innovative services and medical products to the healthcare industry. Other key product areas include pharmacy admixture, nutrition and dialysis. The company is committed to eliminate preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, PA. It is part of the B. Braun Group of Companies in the U.S., including B. Braun Interventional Systems, Aesculap® and CAPS®.
Product Portfolio: The company is involved in manufacturing IV Therapy, Infusion Systems, Vascular Access, Regional Anesthesia, and Pharmacy.
Key Development: On 25th February 2019, B. Braun Medical Inc. has announced the acquisition of Medisystems®' Streamline® Bloodlines business. The acquired bloodline systems will include the Streamline Bloodline for the Dialog+® hemodialysis system, Streamline Bloodline for the Fresenius Medical Care hemodialysis system, and Streamline Bloodline Long for the Fresenius Medical Care hemodialysis system.
The lactated ringers injection market report would provide an access to an approx. 53 market data table, 40 figures and 180 pages.
